阿帕替尼递增剂量治疗晚期胃癌的疗效分析

Efficacy analysis of increasing dose of apatinib in advanced gastric cancer

目的探讨分析使用阿帕替尼递增剂量治疗晚期胃癌的效果。方法选取2017年1月至2018年12月本院收治的肝癌患者134例,随机分为研究组和对照组,各67例。研究组使用阿帕替尼递增剂量,对照组使用常规剂量,比较两组治疗效果、不良反应、生存质量、骨髓抑制和免疫功能。结果研究组治疗效果优于对照组(P<0.05),不良反应总发生率低于对照组(P<0.05),生存质量高于对照组(P<0.05),免疫功能优于对照组(P<0.05),骨髓抑制发生率低于对照组(P<0.05)。结论使用阿帕替尼递增剂量治疗晚期胃癌,可提高治疗效果,降低不良反应发生率,降低骨髓抑制的发生率,提高患者的免疫功能,提高患者的生存质量,具有临床应用的价值。

Objective To investigate the effect of increasing doses of apatinib in the treatment of advanced gastric cancer. Methods A total of134 patients with liver cancer treated in our hospital from January 2017 to December 2018 were randomly divided into study group and control group, with 67 cases in each group. The study group used a dose of apatinib and the control group used a conventional dose. Treatment effect, adverse reactions, quality of life, bone marrow suppression and immune function were compared between two groups. Results The treatment effect of the study group was better than that of the control group(P<0.05), and the incidence of adverse reactions was lower than that of the control group(P<0.05). The quality of life was higher than the control group(P<0.05), and the immune function was better than the control group(P<0.05). The incidence of bone marrow suppression was lower than that of the control group(P<0.05). Conclusion The use of increasing doses of apatinib in the treatment of advanced gastric cancer can improve the therapeutic effect, reduce adverse reactions, reduce the incidence of bone marrow suppression, improve the immune function of patients, and improve the quality of life of patients, so it has clinical application value.